ArticleJAMA network open2022

Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France.

Ombline de Calbiac et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.